Send to

Choose Destination
Cancer Lett. 2013 Mar 1;330(1):57-66. doi: 10.1016/j.canlet.2012.11.020. Epub 2012 Nov 28.

Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label-free proteomics.

Author information

Laboratório de Células Tronco, Instituto Nacional do Câncer, INCA, Rio de Janeiro, Brazil.


This study evaluated the plasmatic proteomic profile of breast cancer patients in the early (ED) and advanced (AD) stages, employing high-throughput proteomics. We identified 92 differentially expressed proteins in ED and 73 proteins in AD patients. Gelsolin, lumican, clusterin, SALL4 and PMS2, as well hTERT, TNF-α and GRHL3 were chosen for further investigation. ED presented augmented expression of GRHL3 and reduced circulating TNF-α with high expression of GRHL3 in tumors. AD displayed high TNF-α and a significant expression of PMS2 in tumors. These findings suggest processes enrolling stem cell division in ED, with TNF-α signaling and DNA mismatch repair in the advanced stage.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center